<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ANADROL-50- oxymetholone tablet </strong><br>Alaven Pharmaceutical<br></p></div>
<h1><span class="Bold">Anadrol<span class="Sup">®</span>-50 (oxymetholone) 50 mg Tablets</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="header"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only   CIII</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Anadrol<span class="Sup">®</span>-50 (oxymetholone) Tablets for oral administration each contain 50 mg of the steroid oxymetholone, a potent anabolic and androgenic drug.</p>
<p>The chemical name for oxymetholone is 17β-hydroxy-2-(hydroxymethylene)-17-methyl-5α-androstan-3-one.  The structural formula is:</p>
<p><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212&amp;name=anadrol-figure-1.jpg"></p>
<p>Inactive Ingredients- lactose, magnesium stearate, povidone, starch</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="pharmacology"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Anabolic steroids are synthetic derivatives of testosterone.  Nitrogen balance is improved with anabolic agents but only when there is sufficient intake of calories and protein.  Whether this positive nitrogen balance is of primary benefit in the utilization of protein-building dietary substances has not been established.  Oxymetholone enhances the production and urinary excretion of erythropoietin in patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> due to <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span> and often stimulates erythropoiesis in <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> due to deficient red cell production.</p>
<p>Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs.  Complete dissociation of anabolic and androgenic effects has not been achieved.  The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children.  They suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Anadrol<span class="Sup">®</span>-50 Tablets is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> caused by deficient red cell production.  Acquired <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, congenital <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="133169" conceptname="Myelofibrosis">myelofibrosis</span> and the <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemias</span> due to the administration of myelotoxic drugs often respond. Anadrol<span class="Sup">®</span>-50 Tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B<span class="Sub">12</span> or <span class="product-label-link" type="condition" conceptid="435787" conceptname="Vitamin B6 deficiency">pyridoxine deficiency</span>, antibacterial therapy and the appropriate use of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li>Carcinoma of the prostate or breast in male patients.</li>
<li>Carcinoma of the breast in females with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>; androgenic anabolic steroids may stimulate osteolytic resorption of bones.</li>
<li>Oxymetholone can cause fetal harm when administered to pregnant women.  It is contraindicated in women who are or may become pregnant.  If the patient becomes pregnant while taking the drug, she should be apprised of the potential hazard to the fetus.</li>
<li><span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span> or the nephrotic phase of <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the drug.</li>
<li>Severe hepatic dysfunction.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The following conditions have been reported in patients receiving androgenic anabolic steroids as a general class of drugs:</p>
<div class="Warning">
<a name="boxed-warning"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis hepatitis</span>, a condition in which liver and sometimes splenic tissue is replaced with blood-filled <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, has been reported in patients receiving androgenic anabolic steroid therapy.  These <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.  They are often not recognized until life-threatening <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> or intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> develops.  Withdrawal of drug usually results in complete disappearance of lesions.  </p>
<p>Liver cell tumors are also reported.  Most often these tumors are benign and androgen-dependent, but fatal <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> have been reported.  Withdrawal of drug often results in regression or cessation of progression of the tumor.  However, hepatic tumors associated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> develops.</p>
<p>Blood lipid changes that are known to be associated with increased risk of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> are seen in patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> and anabolic steroids.  These changes include decreased high density lipoprotein and sometimes increased low density lipoprotein.  The changes may be very marked and could have a serious impact on the risk of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> and <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="warnings-add"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occur with 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> at relatively low doses.  Clinical <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be painless, with or without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.  It may also be associated with acute hepatic enlargement and right upper-quadrant <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, which has been mistaken for acute (surgical) obstruction of the bile duct.  Drug-induced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is usually reversible when the medication is discontinued.  Continued therapy has been associated with <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Because of the hepatoxicity associated with oxymetholone administration, periodic liver function tests are recommended.</p>
<p>In patients with breast cancer, anabolic steroid therapy may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by stimulating <span class="product-label-link" type="condition" conceptid="78308" conceptname="Osteolysis">osteolysis</span>.  In this case, the drug should be discontinued.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be a serious complication in patients with pre-existing cardiac, renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Concomitant administration with adrenal steroids or ACTH may add to the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.  This is generally controllable with appropriate diuretic and/or digitalis therapy.</p>
<p>Geriatric male patients treated with androgenic anabolic steroids may be at an increased risk for the development of prostate <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> and prostatic carcinoma.</p>
<p>Anabolic steroids have not been shown to enhance athletic ability.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">Concurrent dosing of an anabolic steroid and warfarin may result in unexpectedly large increases in the INR or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT).  When an anabolic steroid is prescribed to a patient being treated with warfarin, doses of warfarin may need to be decreased significantly to maintain the desirable INR level and diminish the risk of potentially serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  (See <a href="#interactions">PRECAUTIONS-Drug Interactions.</a>)</span><div class="Section" data-sectionCode="42229-5">
<a name="general"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">Women should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and clitoromegaly).  To prevent irreversible change, drug therapy must be discontinued when mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is first detected.  Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following androgenic anabolic steroid use at high doses.  Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.  Menstrual irregularities, including <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, may also occur.</p>
<p>The insulin or oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.</p>
<p>Anabolic steroids may cause suppression of clotting factors II, V, VII and X, and an increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="information"></a><a name="section-7.2"></a><p></p>
<h2>Information for the patient:</h2>
<p class="First">The health care provider should instruct patients to report immediately any use of warfarin and any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>The health care provider should instruct patients to report any of the following effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="adultmales"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Adult or Adolescent Males: </span>Too frequent or persistent erections of the penis, appearance or aggravation of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="women"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Women: </span><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods or more hair on the face.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="allpatients"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">All Patients: </span>Any <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="laboratorytests"></a><a name="section-7.6"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgenic anabolic steroid therapy (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, liver function tests should be obtained periodically.</p>
<p>Periodic (every 6 months) x-ray examinations of bone age should be made during treatment of prepubertal patients to determine the rate of bone maturation and the effects of androgenic anabolic steroid therapy on the epiphyseal centers.</p>
<p>Anabolic steroids have been reported to lower the level of high-density lipoproteins and raise the level of low-density lipoproteins.  These changes usually revert to normal on discontinuation of treatment.  Increased low-density lipoproteins and decreased high-density lipoproteins are considered cardiovascular risk factors.  Serum lipids and high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> should be determined periodically.</p>
<p>Hemoglobin and hematocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of anabolics.</p>
<p>Because <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> has been observed in some patients treated with oxymetholone, periodic determination of the serum iron and iron binding capacity is recommended. If <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is detected, it should be appropriately treated with supplementary iron.</p>
<p>Oxymetholone has been shown to decrease 17-ketosteroid excretion.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="interactions"></a><a name="section-7.7"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First"><span class="Bold">Warfarin:</span> Clinically significant pharmacokinetic and <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> between anabolic steroids and warfarin have been reported in healthy volunteers. When anabolic steroid therapy is initiated in a patient already receiving treatment with warfarin, the INR (international normalized ratio) or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. Furthermore, in patients receiving both ANADROL<span class="Sup">®</span>-50 Tablets and warfarin, careful monitoring of the INR or PT and adjustment of the warfarin dosage, if indicated, are recommended when the ANADROL®-50 dose is changed or discontinued.  Patients should be closely monitored for signs and symptoms of occult <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Bold">Anticoagulants:</span> Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the desired <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="interferences"></a><a name="section-7.8"></a><p></p>
<h2>Drug/Laboratory Test Interferences:</h2>
<p class="First">Therapy with androgenic anabolic steroids may decrease levels of thyroxine-binding globulin resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged and there is no clinical evidence of thyroid dysfunction. Altered tests usually persist for 2 to 3 weeks after stopping anabolic therapy.</p>
<p>Anabolic steroids may cause an increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
<p>Anabolic steroids have been shown to alter fasting blood sugar and glucose tolerance tests.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="carcinogenesis"></a><a name="section-7.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A two-year carcinogenicity study in rats given oxymetholone orally was conducted under the auspices of the US National Toxicology Program (NTP). A wide spectrum of neoplastic and non-neoplastic effects was observed. In male rats, no effects were classified as neoplastic in response to doses up to 150 mg/kg/day (5 times therapeutic exposures with 5 mg/kg based on body surface area). Female rats given 30 mg/kg/day (1 fold the maximum recommended clinical dose of 5 mg/kg/day based on the body surface area) had increased incidences of lung alveolar/bronchiolar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> or carcinoma combined. At 100 mg/kg/day (about 3 fold the maximum recommended clinical dose of 5 mg/kg/day based on BSA), female rats had increased incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> or carcinoma combined; the combined incidence of squamous cell carcinoma and carcinoma of the sweat glands also was increased.</p>
<p><span class="Underline">Human data:</span> There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
<p>In studies conducted under the auspices of the US National Toxicology Program, no evidence of genotoxicity was found using standard assays for mutagenicity, chromosomal aberrations, or induction of micronuclei in erythrocytes.</p>
<p>Impairment of fertility was not tested directly in animal species. However, as noted below under <span class="Bold"><a href="#ae">ADVERSE REACTIONS</a></span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> in males and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> in females are potential adverse effects of treatment with ANADROL®-50 Tablets. Therefore, impairment of fertility is a possible outcome of treatment with ANADROL®-50 Tablets.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="pregnancy"></a><a name="section-7.10"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First">Pregnancy category X. (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursing"></a><a name="section-7.11"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether anabolics are excreted in human milk. Because of the potential for serious adverse reactions in nursed infants from anabolics, women who take oxymetholone should not nurse.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-7.12"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Anabolic/androgenic steroids should be used very cautiously in children and only by specialists who are aware of their effects on bone maturation.</p>
<p>Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children, and the effect may continue for 6 months after the drug has been stopped. Therefore, therapy should be monitored by x-ray studies at 6-month intervals in order to avoid the risk of compromising the adult height.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-7.13"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">Clinical studies of ANADROL®-50 Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ae"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> with, rarely, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Hepatocellular neoplasms and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> have been reported in association with long-term androgenic anabolic steroid therapy (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p><span class="Bold">Genitourinary System:</span></p>
<p><span class="Bold">In Men: </span></p>
<p>Prepubertal: Phallic enlargement and increased frequency of erections.</p>
<p>Postpubertal: Inhibition of testicular function, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, chronic <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, <span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span>, <span class="product-label-link" type="condition" conceptid="4227848" conceptname="Bladder irritability">bladder irritability</span> and decrease in seminal volume.</p>
<p><span class="Bold">In Women:</span> Clitoral enlargement, menstrual irregularities.</p>
<p><span class="Bold">In Both Sexes:</span> Increased or decreased libido.</p>
<p><span class="Bold">CNS:</span> Excitation, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in patients on concomitant anticoagulant therapy, iron-<span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> has been observed in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> treated with oxymetholone. The role, if any, of oxymetholone is unclear because malignant transformation has been seen in patients with <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> has been reported in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> who have not been treated with oxymetholone.</p>
<p><span class="Bold">Breast:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>.</p>
<p><span class="Bold">Larynx:</span> Deepening of the voice in women.</p>
<p><span class="Bold">Hair:</span> <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span> and male-pattern <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">baldness</span> in women, male-pattern of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> in postpubertal males.</p>
<p><span class="Bold">Skin:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> (especially in women and prepubertal boys).</p>
<p><span class="Bold">Skeletal:</span> Premature closure of epiphyses in children (see <span class="Bold"><a href="#pediatric">PRECAUTIONS, Pediatric Use</a></span>), <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>.</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>.</p>
<p><span class="Bold">Fluid and Electrolytes:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium).</p>
<p><span class="Bold">Metabolic/Endocrine:</span> Decreased glucose tolerance (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>), increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins (see <span class="Bold"><a href="#laboratorytests">PRECAUTIONS, Laboratory Tests</a></span>), increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK). Reversible changes in liver function tests also occur, including increased Bromsulphalein (BSP) retention and increase in serum bilirubin, glutamic-oxaloacetic transaminase (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and alkaline phosphatase.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="drugabusedepend"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"><span class="Bold">Controlled Substance:</span><br>ANADROL®-50 Tablets is considered to be a controlled substance and is listed in Schedule III.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of acute overdosage with anabolics.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended daily dose in children and adults is 1-5 mg/kg of body weight per day. The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose should be individualized. Response is not often immediate, and a minimum trial of three to six months should be given. Following remission, some patients may be maintained without the drug; others may be maintained on an established lower daily dosage. A continued maintenance dose is usually necessary in patients with congenital <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="howsupplied"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ANADROL®-50 (oxymetholone) Tablets is supplied in bottles of 100 (NDC 68220-055-10) white scored tablets embossed with 0055 and ALAVEN. <span class="Bold">Keep out of reach of children.</span> Dispense in a tight, light-resistant container.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="storage"></a><a name="section-13"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP].</p>
<p><span class="Bold">Rx Only</span><br>Manufactured for<br>ALAVEN Pharmaceutical<br>Marietta, GA 30067<br>Anadrol®-50 is a registered trademark of Alaven™ Pharmaceutical<br>Address medical inquiries to:<br>Alaven Pharmaceutical LLC<br>2260 Northwest Parkway, Suite A<br>Marietta, GA 30067<br>Or call toll free<br>1-888-317-0001<br>ALAVEN™ PHARMACEUTICAL<br>055 Rev 12/06 <br>©2006, ALAVEN Pharmaceutical</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="label"></a><a name="section-14"></a><p></p>
<p class="First">Package Label - Principal Display Panel –100 Count Bottle Label<br><br>NDC 68220-055-10<br>100 Tablets  CIII<br>ANADROL-<span class="Sup">®</span>50<br>(oxymetholone)<br>Tablets<br>50 mg<br>Rx Only<br><br>68220-055-10  Rev. 12/06
						</p>
<p><img alt="*Add image Description From Transmittal Form Here*" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212&amp;name=anadrol-figure-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ANADROL-50 		
					</strong><br><span class="contentTableReg">oxymetholone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68220-055</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYMETHOLONE</strong> (OXYMETHOLONE) </td>
<td class="formItem">OXYMETHOLONE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">0055;ALAVEN</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68220-055-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016848</td>
<td class="formItem">06/01/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alaven Pharmaceutical
							(140210829)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alaven Pharmaceutical (140210829)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>251eb269-e7ae-11e1-aff1-0800200c9a66</div>
<div>Set id: 4b9c6c34-9cb2-4d70-b70e-c7ce2fda4212</div>
<div>Version: 4</div>
<div>Effective Time: 20121003</div>
</div>
</div> <div class="DistributorName">Alaven Pharmaceutical</div></p>
</body></html>
